Abu Dhabi has marked a major milestone in regenerative medicine with the completion of a groundbreaking clinical trial aimed at treating knee osteoarthritis using stem cell therapy. The Department of Health – Abu Dhabi, in collaboration with Swedish biotech firm CellColabs and Burjeel Holdings, has successfully tested the safety and efficacy of StromaForte, a stem cell-based treatment targeting degenerative joint disease.
The trial yielded promising results in both safety and effectiveness, representing a significant step forward in the treatment of musculoskeletal conditions through regenerative therapies.
The primary objective of the trial was to evaluate the regenerative potential of mesenchymal stem cells (MSCs), which are known for their anti-inflammatory properties and ability to repair damaged tissue. These stem cells were derived from healthy donors aged between 18 and 30, and were injected directly into the affected knee joint to stimulate the body’s natural healing processes.
The study was conducted between November 2023 and October 2024 at Burjeel Medical City and Burjeel Hospital, under the supervision of orthopaedic surgeons Dr Osama Al Shaar and Dr Veerapahu Muthusamy. Patients received image-guided injections using ultrasound technology to ensure precision.
Initial results from the Phase I/II clinical trial demonstrated that the primary safety goal was met, as confirmed by an independent safety monitoring board. Patients reported a significant reduction in pain levels and noticeable improvement in quality of life, with many regaining comfort in movement and resuming daily activities without any serious side effects. MRI scans were also used to assess the treatment’s effectiveness in improving joint structure.
Dr Asmaa Ibrahim Al Mannaei, Executive Director of the Research and Innovation Centre at the Department of Health – Abu Dhabi, highlighted the broader implications of the trial: “The success of this clinical trial reflects the growing research and medical capabilities in Abu Dhabi. It underscores our commitment to positioning the emirate as a global hub for healthcare innovation.”
She added, “By focusing on gene, cell, and regenerative therapies, we are opening new pathways to improve patient outcomes and enhance overall quality of life.”
The trial was conducted in collaboration with CellColabs, a member of Abu Dhabi’s global tech ecosystem Hub71, and partnership with Burjeel Medical City. Together, they have brought advanced stem cell treatments to patients in the UAE.
Peter Ekstedt, CEO of CellColabs, commented, “This clinical trial marks a significant achievement in Abu Dhabi’s mission to lead in regenerative medicine. We are proud to be part of this innovative healthcare ecosystem and to contribute solutions that enhance the lives of people suffering from osteoarthritis.”
Professor Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, also noted, “The encouraging outcomes of the StromaForte trial highlight the growing role of biotechnology in Abu Dhabi’s healthcare sector. This paves the way for safer, more effective non-surgical treatment options for osteoarthritis patients.”
